Cardiol Pretax Profit Margin vs Net Profit Margin Analysis

CRDL Stock

USD 1.34 0.03 2.19%

Cardiol Therapeutics financial indicator trend analysis is way more than just evaluating Cardiol Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiol Therapeutics is a good investment. Please check the relationship between Cardiol Therapeutics Pretax Profit Margin and its Net Profit Margin accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Pretax Profit Margin vs Net Profit Margin

Pretax Profit Margin vs Net Profit Margin Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiol Therapeutics Pretax Profit Margin account and Net Profit Margin. At this time, the significance of the direction appears to have totally related.

The correlation between Cardiol Therapeutics' Pretax Profit Margin and Net Profit Margin is 1.0. Overlapping area represents the amount of variation of Pretax Profit Margin that can explain the historical movement of Net Profit Margin in the same time period over historical financial statements of Cardiol Therapeutics Class, assuming nothing else is changed. The correlation between historical values of Cardiol Therapeutics' Pretax Profit Margin and Net Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pretax Profit Margin of Cardiol Therapeutics Class are associated (or correlated) with its Net Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Profit Margin has no effect on the direction of Pretax Profit Margin i.e., Cardiol Therapeutics' Pretax Profit Margin and Net Profit Margin go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Pretax Profit Margin

Net Profit Margin

The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.

Most indicators from Cardiol Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

The value of Selling General Administrative is expected to slide to about 14.6 M. The value of Issuance Of Capital Stock is estimated to slide to about 39.4 M

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	219.9K	195.3K	224.6K	182.4K
Interest Income	1.2M	2.2M	2.5M	2.6M

Depreciation And Amortization Interest Income

Cardiol Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Inventory
Total Assets		-0.67	0.82	0.95	1.0	0.96	0.57	-0.99	-0.78	0.74	1.0	-0.34	0.74	1.0	0.49	0.7	-0.72	0.75	0.95	0.96	1.0	0.96	-0.79	0.88	0.57	-0.76
Short Long Term Debt Total	-0.67		-0.52	-0.69	-0.66	-0.6	-0.5	0.71	0.64	-0.62	-0.71	0.21	-0.35	-0.71	-0.2	-0.66	0.96	-0.62	-0.69	-0.6	-0.67	-0.6	0.62	-0.64	-0.51	0.69
Other Current Liab	0.82	-0.52		0.68	0.84	0.72	0.4	-0.84	-0.38	0.29	0.83	-0.02	0.4	0.83	0.29	0.32	-0.57	0.36	0.68	0.72	0.82	0.72	-0.42	0.55	0.42	-0.47
Total Current Liabilities	0.95	-0.69	0.68		0.93	0.99	0.59	-0.94	-0.9	0.86	0.96	-0.51	0.77	0.96	0.38	0.88	-0.71	0.86	1.0	0.99	0.95	0.99	-0.91	0.98	0.56	-0.81
Total Stockholder Equity	1.0	-0.66	0.84	0.93		0.94	0.57	-0.99	-0.74	0.71	0.99	-0.31	0.72	0.99	0.51	0.66	-0.72	0.72	0.93	0.94	1.0	0.94	-0.76	0.85	0.56	-0.74
Net Tangible Assets	0.96	-0.6	0.72	0.99	0.94		0.61	-0.94	-0.87	0.82	0.96	-0.45	0.81	0.96	0.46	0.84	-0.64	0.84	0.99	1.0	0.96	1.0	-0.9	0.97	0.58	-0.8
Property Plant And Equipment Net	0.57	-0.5	0.4	0.59	0.57	0.61		-0.52	-0.7	0.56	0.54	0.26	0.83	0.54	0.75	0.58	-0.68	0.7	0.58	0.61	0.57	0.61	-0.76	0.68	1.0	-0.92
Net Debt	-0.99	0.71	-0.84	-0.94	-0.99	-0.94	-0.52		0.75	-0.71	-1.0	0.35	-0.67	-1.0	-0.42	-0.68	0.74	-0.72	-0.94	-0.94	-0.99	-0.94	0.76	-0.86	-0.52	0.73
Retained Earnings	-0.78	0.64	-0.38	-0.9	-0.74	-0.87	-0.7	0.75		-0.97	-0.78	0.49	-0.81	-0.78	-0.44	-0.92	0.66	-0.98	-0.9	-0.87	-0.78	-0.87	0.98	-0.95	-0.66	0.91
Accounts Payable	0.74	-0.62	0.29	0.86	0.71	0.82	0.56	-0.71	-0.97		0.75	-0.62	0.75	0.75	0.39	0.9	-0.6	0.97	0.86	0.82	0.74	0.82	-0.92	0.91	0.52	-0.82
Cash	1.0	-0.71	0.83	0.96	0.99	0.96	0.54	-1.0	-0.78	0.75		-0.39	0.7	1.0	0.42	0.72	-0.74	0.75	0.96	0.96	1.0	0.96	-0.79	0.89	0.53	-0.75
Non Current Assets Total	-0.34	0.21	-0.02	-0.51	-0.31	-0.45	0.26	0.35	0.49	-0.62	-0.39		-0.15	-0.39	0.33	-0.57	0.02	-0.48	-0.51	-0.46	-0.35	-0.46	0.41	-0.48	0.31	0.11
Long Term Debt	0.74	-0.35	0.4	0.77	0.72	0.81	0.83	-0.67	-0.81	0.75	0.7	-0.15		0.7	0.71	0.71	-0.51	0.81	0.77	0.81	0.73	0.81	-0.88	0.85	0.81	-0.86
Cash And Short Term Investments	1.0	-0.71	0.83	0.96	0.99	0.96	0.54	-1.0	-0.78	0.75	1.0	-0.39	0.7		0.42	0.72	-0.74	0.75	0.96	0.96	1.0	0.96	-0.79	0.89	0.53	-0.75
Net Receivables	0.49	-0.2	0.29	0.38	0.51	0.46	0.75	-0.42	-0.44	0.39	0.42	0.33	0.71	0.42		0.28	-0.4	0.44	0.38	0.46	0.49	0.45	-0.48	0.45	0.76	-0.61
Common Stock Shares Outstanding	0.7	-0.66	0.32	0.88	0.66	0.84	0.58	-0.68	-0.92	0.9	0.72	-0.57	0.71	0.72	0.28		-0.64	0.88	0.88	0.84	0.7	0.84	-0.93	0.94	0.53	-0.8
Non Current Liabilities Total	-0.72	0.96	-0.57	-0.71	-0.72	-0.64	-0.68	0.74	0.66	-0.6	-0.74	0.02	-0.51	-0.74	-0.4	-0.64		-0.64	-0.7	-0.64	-0.72	-0.64	0.67	-0.68	-0.7	0.8
Other Stockholder Equity	0.75	-0.62	0.36	0.86	0.72	0.84	0.7	-0.72	-0.98	0.97	0.75	-0.48	0.81	0.75	0.44	0.88	-0.64		0.86	0.84	0.75	0.84	-0.96	0.92	0.67	-0.9
Total Liab	0.95	-0.69	0.68	1.0	0.93	0.99	0.58	-0.94	-0.9	0.86	0.96	-0.51	0.77	0.96	0.38	0.88	-0.7	0.86		0.99	0.95	0.99	-0.91	0.98	0.56	-0.81
Net Invested Capital	0.96	-0.6	0.72	0.99	0.94	1.0	0.61	-0.94	-0.87	0.82	0.96	-0.46	0.81	0.96	0.46	0.84	-0.64	0.84	0.99		0.96	1.0	-0.89	0.97	0.58	-0.8
Total Current Assets	1.0	-0.67	0.82	0.95	1.0	0.96	0.57	-0.99	-0.78	0.74	1.0	-0.35	0.73	1.0	0.49	0.7	-0.72	0.75	0.95	0.96		0.96	-0.79	0.88	0.56	-0.75
Net Working Capital	0.96	-0.6	0.72	0.99	0.94	1.0	0.61	-0.94	-0.87	0.82	0.96	-0.46	0.81	0.96	0.45	0.84	-0.64	0.84	0.99	1.0	0.96		-0.89	0.97	0.58	-0.8
Intangible Assets	-0.79	0.62	-0.42	-0.91	-0.76	-0.9	-0.76	0.76	0.98	-0.92	-0.79	0.41	-0.88	-0.79	-0.48	-0.93	0.67	-0.96	-0.91	-0.89	-0.79	-0.89		-0.97	-0.73	0.94
Common Stock	0.88	-0.64	0.55	0.98	0.85	0.97	0.68	-0.86	-0.95	0.91	0.89	-0.48	0.85	0.89	0.45	0.94	-0.68	0.92	0.98	0.97	0.88	0.97	-0.97		0.64	-0.87
Property Plant Equipment	0.57	-0.51	0.42	0.56	0.56	0.58	1.0	-0.52	-0.66	0.52	0.53	0.31	0.81	0.53	0.76	0.53	-0.7	0.67	0.56	0.58	0.56	0.58	-0.73	0.64		-0.9
Inventory	-0.76	0.69	-0.47	-0.81	-0.74	-0.8	-0.92	0.73	0.91	-0.82	-0.75	0.11	-0.86	-0.75	-0.61	-0.8	0.8	-0.9	-0.81	-0.8	-0.75	-0.8	0.94	-0.87	-0.9

Click cells to compare fundamentals

Cardiol Therapeutics Account Relationship Matchups

Cardiol Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.9M	87.9M	62.0M	36.7M	42.2M	38.6M
Short Long Term Debt Total	156.6K	117.6K	72.9K	174.3K	156.9K	133.9K
Other Current Liab	696.1K	7.4M	1.4M	655.0K	753.2K	715.6K
Total Current Liabilities	2.5M	11.6M	9.8M	8.3M	9.5M	5.5M
Total Stockholder Equity	13.3M	76.2M	52.2M	28.2M	32.5M	33.0M
Net Tangible Assets	14.1M	12.8M	75.9M	51.9M	59.7M	32.7M
Property Plant And Equipment Net	479.6K	356.5K	295.7K	337.1K	387.6K	329.6K
Net Debt	(13.9M)	(83.8M)	(59.4M)	(34.8M)	(31.3M)	(32.8M)
Retained Earnings	(51.9M)	(83.5M)	(114.4M)	(142.6M)	(128.3M)	(121.9M)
Accounts Payable	1.8M	4.1M	8.3M	7.6M	8.8M	9.2M
Cash	14.0M	83.9M	59.5M	34.9M	40.2M	34.3M
Non Current Assets Total	943.2K	735.7K	590.5K	547.4K	492.7K	610.6K
Cash And Short Term Investments	14.0M	83.9M	59.5M	34.9M	40.2M	34.3M
Net Receivables	219.9K	407.1K	480.2K	279.9K	321.9K	452.2K
Common Stock Shares Outstanding	29.9M	43.2M	62.5M	64.5M	74.1M	41.5M
Liabilities And Stockholders Equity	15.9M	87.9M	62.0M	36.7M	42.2M	38.6M
Non Current Liabilities Total	104.7K	72.9K	22.4K	158.5K	142.7K	109.5K
Other Stockholder Equity	8.8M	12.7M	15.6M	18.8M	21.6M	22.7M
Total Liab	2.6M	11.6M	9.8M	8.5M	9.7M	5.7M
Net Invested Capital	14.7M	13.3M	76.2M	52.2M	60.0M	33.4M
Total Current Assets	14.9M	87.1M	61.4M	36.2M	41.6M	37.8M
Net Working Capital	13.7M	12.4M	75.6M	51.6M	59.4M	32.5M
Intangible Assets	463.7K	379.2K	294.8K	210.4K	189.3K	371.0K
Common Stock	51.9M	142.9M	147.5M	148.5M	170.8M	89.8M
Property Plant Equipment	584.0K	479.6K	356.5K	295.7K	340.1K	322.7K
Inventory	1.1M	18.0K	339.1K	(279.9K)	(251.9K)	(239.3K)
Other Current Assets	347.8K	2.8M	1.5M	1.2M	1.1M	1.6M
Capital Stock	39.4M	51.9M	142.9M	147.5M	169.7M	92.1M
Current Deferred Revenue	(1.8M)	(4.2M)	(8.3M)	(7.6M)	(6.9M)	(7.2M)
Short Term Debt	51.9K	44.7K	50.4K	15.8K	14.2K	13.5K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:

How To Invest In Cardiol

Details

Is Cardiol Stock a good investment?

Details

What is Cardiol Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.38)

Return On Assets

(0.54)

Return On Equity

(1.08)

The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cardiol Pretax Profit Margin vs Net Profit Margin Analysis

Pretax Profit Margin vs Net Profit Margin

Pretax Profit Margin vs Net Profit Margin Correlation Analysis

Correlation Coefficient

Pretax Profit Margin

Net Profit Margin

Cardiol Therapeutics fundamental ratios Correlations

Cardiol Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cardiol Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.98	Retained Earnings